This study was a nationwide, population based study in Spain that utilized  two-stage random sampling stratified by province and municipality size. From April 27 to May 11, 2020, 61,075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire. 



Seroprevalence was 5·0% (95% CI 4·7–5·4) by the point-of-care test and 4·6% (4·3–5·0) by immunoassay. There was substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%). 



In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15·3% (13·8–16·8) to 19·3% (17·7–21·0). Around a third of seropositive participants were asymptomatic, ranging from 21·9% (19·1–24·9) to 35·8% (33·1–38·5). Only 19·5% (16·3–23·2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test.

Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

University of Michigan - Ann Arbor

SARS-CoV-2 seroprevalence is the proportion of a defined population with detectable antibodies against SARS-CoV-2. It is estimated through antibody testing, and estimates can vary with population sampling, inclusion of asymptomatic infections, test-result definitions, and the cost of large-scale specimen collection.

Learn Before

Related

Learn After